UnknownNot Applicable

Inherited Cancer Early Diagnosis (ICED) Study

United Kingdom100 participantsStarted 2022-07-26

Plain-language summary

ICED is a prospective sample collection research study, aiming to develop or validate a blood/urine biomarker which could potentially detect cancers early in individuals at high risk of developing cancers, due to certain germline alterations.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients over the age of 18 years old, with no active cancer
✓. Carriers of a pathogenic/likely pathogenic variant in any of the following genes: TP53, Mismatch Repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM), PTEN, STK11 (Peutz-Jeghers syndrome), CDH1, APC, SMAD4, MUTYH\* (\*biallelic carriers).
✓. Able to consent to the study.

Exclusion criteria

✕. Carriers of a variant associated with reduced penetrance (in the view of a geneticist) or a variant of uncertain significance.
✕. Patients with a malignancy diagnosed in the previous 5 years \[except non-melanomatous skin cancer or cervical carcinoma in situ (CIS)\].

What they're measuring

Primary hypothesis

Timeframe: 2 years

Trial details

NCT IDNCT06163365

SponsorRoyal Marsden NHS Foundation Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-07-26

Contact for this trial

Elena Cojocaru

020 3186 5384 elena.cojocaru@rmh.nhs.uk

View on ClinicalTrials.gov More Li Fraumeni Syndrome trials